Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 357

1.

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.

Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D.

Cytokine Growth Factor Rev. 2004 Dec;15(6):457-75. Review.

PMID:
15561602
2.

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Hofbauer LC, Heufelder AE.

J Mol Med (Berl). 2001 Jun;79(5-6):243-53. Review.

PMID:
11485016
4.
5.

Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.

Kon T, Cho TJ, Aizawa T, Yamazaki M, Nooh N, Graves D, Gerstenfeld LC, Einhorn TA.

J Bone Miner Res. 2001 Jun;16(6):1004-14.

6.
7.

[New paradigms in the regulation of bone metabolism].

Rosa-Rañal M, de la Cruz DA, Lorena-Rubio Y, Larrea F.

Rev Invest Clin. 2001 Jul-Aug;53(4):362-9. Spanish.

PMID:
11599485
10.

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

Kostenuik PJ, Shalhoub V.

Curr Pharm Des. 2001 May;7(8):613-35. Review.

PMID:
11375772
11.

Key roles of the OPG-RANK-RANKL system in bone oncology.

Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D, Padrines M.

Expert Rev Anticancer Ther. 2007 Feb;7(2):221-32. Review.

PMID:
17288531
12.

Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.

Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.

Biochem Biophys Res Commun. 2006 Aug 25;347(2):460-7. Epub 2006 Jun 30.

PMID:
16828054
13.

RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.

Schoppet M, Preissner KT, Hofbauer LC.

Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):549-53. Review.

14.

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.

Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA.

Cancer. 2006 Jul 15;107(2):289-98.

15.

Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.

Hofbauer LC, Kluger S, Kühne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE.

J Cell Biochem. 2002;86(4):642-50.

PMID:
12210731
16.

Crystal structure of RANK ligand involved in bone metabolism.

Ito S, Hata T.

Vitam Horm. 2004;67:19-33. Review.

PMID:
15110169
18.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

19.
20.

RANKL-RANK signaling in osteoclastogenesis and bone disease.

Wada T, Nakashima T, Hiroshi N, Penninger JM.

Trends Mol Med. 2006 Jan;12(1):17-25. Epub 2005 Dec 13. Review.

PMID:
16356770

Supplemental Content

Support Center